Project Search Results

Select

Research Categorization

Operator
Operator

Project Details

Operator
Operator

Contact Researcher and Awardee Organization

Operator
Operator

Funding Organization

Operator
Operator
Operator
Operator
ListGraphMap
Displaying 1 - 10 of 62 Projects
Project # Contact PI Funding Organization Fiscal Year
Validation of the Retinal Deep Phenotyping (TM) platform for the detection of the likely cerebral amyloid status to aid in the diagnosis of Alzheimer's disease
ADDF-31 Sylvestre, Jean-Philippe Alzheimer's Drug Discovery Foundation 2021
Measurement of immune cell recruitment as a biomarker of neuroinflammation in Alzheimer's disease and other diseases of the central nervous system
ADDF-32 Menniti, Frank Alzheimer's Drug Discovery Foundation 2021
Can Lifestyle Changes Stop or Reverse the Progression of MCI Due to Early-Stage Alzheimer's Disease?
ADDF-37 Ornish, Dean Alzheimer's Drug Discovery Foundation 2021
Easy and early plasma pTau181 detection with LUMIPULSE G platform as indicator of Alzheimer's disease
ADDF-38 Vandijck, Manu Alzheimer's Drug Discovery Foundation 2021
Effects of Chaperone-Mediated Autophagy in Alzheimer's Disease
ADDF-39 Cermak, Jennifer Alzheimer's Drug Discovery Foundation 2021
Clinical Trials for Alzheimer's Disease CTAD
ADDF-40 Touchon, Nathanaelle Alzheimer's Drug Discovery Foundation 2021
Validation and commercialization of a novel blood-based, ultra-multiplex Laboratory Developed Test (LDT) for the prediction of cerebral amyloid status before clinical onset of dementia
ADDF-41 Anderson, Leyla Alzheimer's Drug Discovery Foundation 2021
MIB-626 For Treatment of Mild Dementia Patients
ADDF-43 Livingston, David Alzheimer's Drug Discovery Foundation 2021
Development of a Biosample Database to Investigate Beta-Amyloid, Phospho-Tau, and Neurofilament Light Chain Blood-Based and Digital Biomarkers in Older Volunteers Screened for Preclinical AD, Prodromal AD, or Mild AD
ADDF-47 Beauregard, Doug Alzheimer's Drug Discovery Foundation 2021
Testing low-dose efavirenz treatment for Alzheimer’s disease: a phase 1b dosing, target-engagement and exploratory biomarker study.
ADDF-48 SCHELTENS, PHILIP Alzheimer's Drug Discovery Foundation 2021